|
|
Profile
|
Delegates :
Kenji Kakuta |
|
Incorporated :
April 18 , 2013 |
Paid in Capital :
10 Million yen |
Employees :
10 人 |
Address :
Kyoto Univ. Med-Pharm Collaboration Bldg., 46 Yoshidashimoadachicho, Sakyo-ku, Kyoto-shi, KYOTO
〒606-8304
|
TEL/FAX :
+81-50-5317-7874 / |
URL：
http://www.iheartjapan.jp/en/ |
Attachment :
|
Mission/Background :
iHeart Japan Corporation is developing regenerative medicinal products made from iPS cells,
to save many lives by providing a new medical treatment for heart disease. |
|
Technology & Business
|
Our technology is to differentiate human iPSC into cardiovascular cells. Multi-layered cardiovascular cell sheets worked highly effective in animal model. A clinical trial is planned to start in 2020.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
IHJ-301
|
Preclinical
|
Allogeneic layered cell-sheets-product of mixture of cardiac cells differentiated from human iPSC
|
A clinical trial is planned to start in 2020.
|
MiraCell endothelial Cells
|
Service/Marketing
|
highly pure endothelial cells from iPSC
|
|
MiraCell Cardiomyocytes
|
Service/Marketing
|
highly pure cardiomyocytes from human iPSC
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
The cell processing center was built up in April 2018.
|
|
Alliance strategy
|
Searching for co-development or license of IHJ-301, the regenerative medicinal product for heart failure.
|
|
|